Modern Advancement in Biotechnological Applications for Wastewater Treatment through Microalgae: a Review

ABSTRACT: Microalgae are microscopic organisms that have a broad range of applications, from wastewater treatment, CO2 mitigation to therapeutic proteins, and pharmaceuticals. Recently, the combination of wastewater treatment-based microalgae and the use of the obtained biomass as biofertilizers/stimulants/pesticides have been highly emphasized for their use in the agriculture field. Biofertilizers are a need of today's agriculture practices due to the increasing demand for food to feed a hungry planet while avoiding chemical contamination by the over-application of synthetic fertilizers. There is a constant need for modern techniques for the use of microalgae in a sustainable manner to harness their products to their full extent. Various types of bioreactors are available on the market, each with its own advantages and disadvantages, which, based on their efficiency, can be used for microalgae cultivation. This review aims at reporting recent developments in microalgae biotechnology, especially related to CO2 mitigation, wastewater purification, biofuel, feedstock, future food, therapeutic proteins, pharmaceuticals, and biofertilizers, highlighting some of the current research in this field and future development priorities.info:eu-repo/semantics/publishedVersio

Biosynthesis and characterization of silver nanoparticles generated from peels of Solanum tuberosum (potato) and their antibacterial and wastewater treatment potential

Global food production consumes a large fraction of energy budget, land area, and freshwater; however, a larger fraction of the produce is lost or unutilized, which has potential to produce useful products for human use. The biogenic synthesis of silver nanoparticles from such waste food appears to be a promising strategy. A conservative estimate of 70–140 thousand tons of potato peels is produced annually by food-chain companies globally; however, they are primarily utilized to produce substandard feed for livestock or manure. For the formation of highly profitable compounds, enhancement of value, and the process of extraction, such as nanocomposite, organic antioxidants, and organic meal inclusions, potato peels can be used as a cheap, productive, and readily available source of raw material. In the present research, silver nanoparticles (AgNPs) were extracted from the peels of potato (Solanum tuberosum). The fabrication of potato peel-derived AgNPs was established using UV-visible spectroscopy analysis. Approaches like X-ray diffraction (XRD), attenuated total reflection-infrared (ATR-IR) spectroscopy analysis, and field emission scanning electron microscopy (FESEM) were used to determine the characteristics of the AgNPs. Additionally, strains of Gram-positive bacteria such as Staphylococcus aureus (S. aureus) (ATCC 25923) and Gram-negative bacteria such as Escherichia coli (E. coli) (ATCC 25922) were used to determine the antibacterial activity of AgNPs via the disc diffusion technique. The antibacterial properties of AgNPs could help protect food from microbial contamination. Furthermore, AgNPs were tested for their potential application in purification of industrial wastewater. The results revealed that AgNPs derived from the potato peels could be used in industrial and biomedical applications and possess excellent antibacterial activity. Our research suggests that AgNPs can be extracted from a safe and ecofriendly fabrication technique from largely unused potato peels that have a great potential for inhibiting the bacterial growth and for the in situ purification of wastewater in the upcoming years. Therefore, besides value addition to the farm produce, such recycling of potato peels is likely to reduce the burden of the solid waste volumes in agro-centers, kitchen wastes, and food industries across the globe

Hydroxychloroquine: A Comprehensive Review and Its Controversial Role in Coronavirus Disease 2019

Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and anti-inflammatory agent for the management of autoimmune and rheumatic diseases such as systemic lupus erythematosus. Lately, there has been interest in its potential efficacy against severe acute respiratory syndrome coronavirus 2, with several speculated mechanisms. The purpose of this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is an in-depth analysis of the antimalarial, immunomodulatory, and antiviral mechanisms of hydroxychloroquine, with detailed and novel pictorial explanations. The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for coronavirus disease 2019 (COVID-19). Finally, current literature associated with hydroxychloroquine and COVID-19 has been analyzed to interrelate the mechanisms, adverse effects, and use of hydroxychloroquine in the current pandemic. Currently, there is insufficient evidence about the efficacy and safety of hydroxychloroquine in COVID-19.KEY MESSAGES HCQ, initially an antimalarial agent, is used as an immunomodulatory agent for managing several autoimmune diseases, for which its efficacy is linked to inhibiting lysosomal antigen processing, MHC-II antigen presentation, and TLR functions. HCQ is generally well-tolerated although severe life-threatening adverse effects including cardiomyopathy and conduction defects have been reported. HCQ use in COVID-19 should be discouraged outside clinical trials under strict medical supervision

The 2nd competition on counter measures to 2D face spoofing attacks

Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. I. Chingovska, J. Yang, Z. Lei, D. Yi, S. Z. Li, O. Kahm, C. Glaser, N. Damer, A. Kuijper, A. Nouak, J. Komulainen, T. Pereira, S. Gupta, S. Khandelwal, S. Bansal, A. Rai, T. Krishna, D. Goyal, M.-A. Waris, H. Zhang, I. Ahmad, S. Kiranyaz, M. Gabbouj, R. Tronci, M. Pili, N. Sirena, F. Roli, J. Galbally, J. Fiérrez, A. Pinto, H. Pedrini, W. S. Schwartz, A. Rocha, A. Anjos, S. Marcel, "The 2nd competition on counter measures to 2D face spoofing attacks" in International Conference on Biometrics (ICB), Madrid (Spain), 2013, 1-6As a crucial security problem, anti-spoofing in biometrics, and particularly for the face modality, has achieved great progress in the recent years. Still, new threats arrive inform of better, more realistic and more sophisticated spoofing attacks. The objective of the 2nd Competition on Counter Measures to 2D Face Spoofing Attacks is to challenge researchers to create counter measures effectively detecting a variety of attacks. The submitted propositions are evaluated on the Replay-Attack database and the achieved results are presented in this paper.The authors would like to thank the Swiss Innovation Agency (CTI Project Replay) and the FP7 European TABULA RASA Project4 (257289) for their financial support

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic